Naghavi Saba, Pourmohammadi Ahmad, Adibi Iman
Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Neurol Ther. 2021 Jun;10(1):401-406. doi: 10.1007/s40120-021-00232-9. Epub 2021 Jan 30.
Protein S deficiency is a thrombophilia associated with an increased risk of thromboembolism. Previous studies have shown its role as a predisposing factor for venous thromboembolism, but its role in recurrent arterial ischemic stroke remains uncertain. Here we report a patient with recurrent ischemic stroke due to protein S deficiency. Oral anticoagulant treatment with vitamin K antagonist (VKA) drugs is used to treat and prevent thromboembolic events caused by thrombophilia, but it has many limitations, especially in the case of recurrent thromboembolic events. Direct oral anticoagulants (DOACs) have many advantages over VKA. Previous studies have shown that they are safe in cases of thrombophilia, but they are not well studied in recurrent ischemic stroke due to protein S deficiency. In this study our patient was treated with rivaroxaban. Protein S deficiency may be a predisposing factor in recurrent ischemic stroke, and rivaroxaban can be a safe and effective treatment option. Further studies are needed to confirm our findings.
蛋白S缺乏是一种与血栓栓塞风险增加相关的易栓症。先前的研究已表明其作为静脉血栓栓塞的易感因素的作用,但其在复发性动脉缺血性卒中中的作用仍不确定。在此我们报告一名因蛋白S缺乏导致复发性缺血性卒中的患者。使用维生素K拮抗剂(VKA)药物进行口服抗凝治疗用于治疗和预防由易栓症引起的血栓栓塞事件,但它有许多局限性,尤其是在复发性血栓栓塞事件的情况下。直接口服抗凝剂(DOACs)相对于VKA有许多优势。先前的研究表明它们在易栓症病例中是安全的,但在因蛋白S缺乏导致的复发性缺血性卒中方面研究不足。在本研究中,我们的患者接受了利伐沙班治疗。蛋白S缺乏可能是复发性缺血性卒中的一个易感因素,并且利伐沙班可以是一种安全有效的治疗选择。需要进一步的研究来证实我们的发现。